Inflammasomes in Alzheimer’s Progression: Nrf2 as a Preventive Target
Antioxidants,
Год журнала:
2025,
Номер
14(2), С. 121 - 121
Опубликована: Янв. 21, 2025
Current
knowledge
about
Alzheimer’s
disease
highlights
the
accumulation
of
β-amyloid
plaques
(Aβ1–42)
and
neurofibrillary
tangles
composed
hyperphosphorylated
Tau,
which
lead
to
loss
neuronal
connections.
Microglial
activation
release
inflammatory
mediators
play
a
significant
role
in
progression
pathology.
Recent
advances
have
identified
involvement
inflammasomes,
particularly
NOD-like
receptor
NLR
family
pyrin
domain
containing
3
(NLRP3),
whose
promotes
proinflammatory
cytokines
triggers
pyroptosis,
exacerbating
neuroinflammation.
Aggregates
Aβ1–42
Tau
been
shown
activate
these
while
apoptosis-associated
speck-like
protein
(ASC)
components
form
aggregates
that
further
accelerate
Aβ
aggregation.
Defects
autophagic
clearance
inflammasomes
also
implicated
disease,
contributing
sustained
inflammation.
This
review
explores
strategies
counteract
inflammation
Alzheimer’s,
emphasizing
degradation
ASC
specks
inhibition
NLRP3
inflammasome
activation.
Notably,
nuclear
factor
erythroid
2-related
2
(Nrf2)
transcription
emerges
as
promising
therapeutic
target
due
its
dual
mitigating
oxidative
stress
directly
inhibiting
formation.
By
reducing
inflammasome-driven
inflammation,
Nrf2
offers
potential
for
addressing
neuroinflammatory
aspects
disease.
Язык: Английский
Association Between Hypoxia‐Inducible Factor‐1α and Neurological Diseases: A Bidirectional Two‐Sample Mendelian Randomization Analysis
Brain and Behavior,
Год журнала:
2025,
Номер
15(3)
Опубликована: Фев. 28, 2025
ABSTRACT
Background
Previous
studies
have
suggested
that
hypoxia‐inducible
factor
1‐α
(HIF‐1α)
exerted
multiple
effects
on
different
central
nervous
system
disorders.
However,
it
is
still
uncertain
whether
plasma
HIF‐1α
can
be
a
causal
indicator
for
the
relevant
diseases.
This
study
aimed
to
test
causality
relationship
between
and
neurological
diseases,
including
cerebrovascular
migraines,
neurodegenerative
diseases
with
Mendelian
randomization
(MR)
method.
Methods
Single‐nucleotide
polymorphisms
(SNPs)
genetically
representing
were
screened
as
instrumental
variables
(IVs).
Summary‐level
data
disorder
from
genome‐wide
association
(GWAS)
identified
outcomes.
The
IVs
outcomes
determined
via
major
analysis
of
inverse‐variance‐weighted
(IVW)
reverse
direction
was
also
performed
investigate
possibility
causation.
Results
findings
revealed
associated
cardioembolic
stroke
(CES)
(OR
=
0.885;
95%
confidence
interval
[CI]
0.796–0.985,
p
0.026),
migraine
0.941,
CI
0.888–0.998,
0.041),
drug‐induced
without
aura
(MOA)
0.586,
0.375–0.916,
0.019).
There
no
in
subarachnoid
hemorrhage
(SAH),
other
subtype,
reverse‐MR
above‐stated
did
not
effect
levels.
Sensitivity
validation
analyses
support
above
results
are
stable.
Conclusions
Our
research
indicated
may
risk
CES,
MOA,
providing
new
insights
those
disease
prevention
therapeutic
approaches.
Язык: Английский